Search | Clinical Trials Finder

Conditions: Rheumatoid Arthritis
Interventions: ART621, Placebo; Drug
Lead sponsor: Arana Therapeutics Ltd; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 6
States / cities: Tampa, Florida • Springfield, Illinois • Lincoln, Nebraska + 3 more

Conditions: Graft Vs Host Disease
Interventions: Placebo, Abatacept; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Rheumatoid Arthritis
Interventions: BMS-986142, Placebo, Methotrexate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 26
States / cities: Huntsville, Alabama • Fullerton, California • Hemet, California + 20 more

Conditions: Arthritis, Rheumatoid
Interventions: Golimumab, Placebo, methotrexate (MTX); Drug · Other
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 9
States / cities: Daytona Beach, Florida • Miami, Florida • Palm Harbor, Florida + 6 more

Conditions: Psoriatic Arthritis
Interventions: Etanercept, Methotrexate, Placebo to Etanercept, Placebo to Methotrexate; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 851 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 55
States / cities: Tuscaloosa, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX); Biological · Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 915 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 62
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo matched to atacicept, Atacicept: with loading dose, Atacicept, Adalimumab; Drug · Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: VX-509, VX-509 matching placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 31
States / cities: Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 28 more

Conditions: Rheumatoid Arthritis
Interventions: Leflunomide, Methotrexate, Ocrelizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 144
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more

Conditions: Rheumatoid Arthritis
Interventions: natalizumab, placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 10
States / cities: Birmingham, Alabama • Tucson, Arizona • Escondido, California + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab, Placebo; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more

Conditions: Rheumatoid Arthritis
Interventions: Tofacitinib, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 36
States / cities: Jonesboro, Arkansas • Los Angeles, California • Santa Maria, California + 26 more

Conditions: Psoriatic Arthritis
Interventions: Alefacept, Methotrexate, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: Birmingham, Alabama • Wheaton, Maryland • Lake Success, New York + 2 more

Conditions: Rheumatoid Arthritis
Interventions: M2591 25 mg QD, M2951 75 mg QD, M2951 50 mg BID, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Phoenix, Arizona • San Leandro, California • DeBary, Florida + 3 more

Conditions: Rheumatoid Arthritis
Interventions: MM-093; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 20
States / cities: Montgomery, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 16 more

Conditions: Rheumatoid Arthritis
Interventions: CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc, Placebo iv; Biological · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 74
States / cities: Mesa, Arizona • Paradise Valley, Arizona • Scottsdale, Arizona + 66 more

Conditions: Rheumatoid Arthritis
Interventions: BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo, Adalimumab; Drug · Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 13
States / cities: Peoria, Arizona • San Diego, California • Trumbull, Connecticut + 10 more

Conditions: Rheumatoid Arthritis
Interventions: etanercept pre-filled syringe subcutaneous injection, Oral methotrexate, Placebo for etanercept subcutaneous injection, Placebo for methotrexate, Folic acid (non-investigational product); Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 74
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 68 more

Conditions: Rheumatoid Arthritis
Interventions: BG9924, Placebo Comparator; Biological · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Rheumatoid Arthritis
Interventions: CP-690,550, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 51
States / cities: Gilbert, Arizona • Paradise Valley, Arizona • Jonesboro, Arkansas + 45 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 109
States / cities: Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions: GVAX, Placebo Vaccine, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan, Fludarabine, Tacrolimus, Methotrexate; Biological · Procedure · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 64
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more

Conditions: Rheumatoid Arthritis
Interventions: PLX5622, Placebo; Drug
Lead sponsor: Plexxikon; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 4
States / cities: Anniston, Alabama • Lansing, Michigan • Duncansville, Pennsylvania + 1 more

Search by objective public record fields.

Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis

An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

GVAX vs. Placebo for MDS/AML After Allo HSCT

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate